Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease

Nature Clinical Practice Nephrology

Volumn 5, Issue 1, 2009, Pages 12-13

  Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Progression of CKD; Proteinuria; RAS blockade

Indexed keywords

CAPTOPRIL; RAMIPRIL; TELMISARTAN;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; KIDNEY DISEASE; MONOTHERAPY; NOTE; ORGAN INJURY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 57749189591     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0980     Document Type: Note

References (9)

1. Lewis EJ et al. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329: 1456-1462
2. De Jong PE et al. (1999) Renoprotective therapy: titration against urinary protein excretion. Lancet 354: 352-353
3. De Zeeuw D et al. (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927
4. Nakao N et al. (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124
5. Wolf G and Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812
6. Mann JFE et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind controlled trial. Lancet 372: 547-553
7. Fisher ND and Hollenberg NK (2005) Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 16: 592-599
8. Epstein M (2006) Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119: 912-919
9. ONTARGET investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559